Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4163 |
Name | ganglioneuroblastoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer peripheral nervous system neoplasm autonomic nervous system neoplasm neuroblastoma ganglioneuroblastoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ALK I1171T | Ceritinib | ganglioneuroblastoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01175356 | Phase I | Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Sulfate Cisplatin + Etoposide | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | Active, not recruiting | USA | 0 |
NCT02095132 | Phase Ib/II | Adavosertib + Irinotecan | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02311621 | Phase I | CE7R CAR-T cells | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | Active, not recruiting | USA | 0 |
NCT02559778 | Phase I | Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) | Recruiting | USA | CAN | 0 |
NCT03332667 | Phase I | 131I-MIBG + Dinutuximab + Sargramostim + Vorinostat 131I-MIBG + Dinutuximab + Sargramostim | MIBG With Dinutuximab +/- Vorinostat | Active, not recruiting | USA | 0 |
NCT03721068 | Phase I | iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma | Recruiting | USA | 0 |
NCT03786783 | Phase II | Isotretinoin Cyclophosphamide + Thiotepa Cisplatin + Dinutuximab + Etoposide + Sargramostim Cyclophosphamide + Dinutuximab + Doxorubicin + Sargramostim + Vincristine Sulfate Dexrazoxane Cyclophosphamide + Topotecan Dinutuximab + Isotretinoin + Sargramostim Carboplatin + Etoposide + Melphalan | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | Active, not recruiting | USA | NZL | AUS | 0 |
NCT03794349 | Phase II | Dinutuximab + Irinotecan + Sargramostim + Temozolomide Dinutuximab + Eflornithine + Irinotecan + Sargramostim + Temozolomide | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT04211675 | Phase Ib/II | Dinutuximab + Irinotecan + Sargramostim + Temozolomide | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING) | Recruiting | USA | 0 |
NCT05421897 | FDA approved | Cyclophosphamide + Dinutuximab + Irinotecan + Sargramostim + Temozolomide + Topotecan | Rapid Administration Pilot for Infusing Dinutuximab (RAPID) | Suspended | USA | 0 |
NCT05489887 | Phase II | Ceritinib + Naxitamab Naxitamab | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Recruiting | USA | CAN | 0 |
NCT06172296 | Phase III | Cyclophosphamide + Topotecan Cisplatin + Etoposide Dinutuximab + Irinotecan + Temozolomide Cisplatin + Dinutuximab + Etoposide Dinutuximab beta + Temozolomide Cisplatin + Cyclophosphamide + Dexrazoxane + Dinutuximab + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate Dinutuximab + Isotretinoin Carboplatin + Cyclophosphamide + Etoposide + Melphalan + Thiotepa Cisplatin + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Recruiting | USA | NZL | CAN | 0 |